Capital and diligence, built on regulatory judgment most investors do not have in-house.

Tacticity Capital is backed by our own family office and invests in healthcare, medtech, IVD, and SaMD companies at the angel and early stages. Every investment and diligence decision is informed directly by former U.S. FDA reviewer judgment, the same expertise that underpins Tacticity Advisors' regulatory practice. This is not capital with regulatory consulting attached. It is capital that starts from a regulatory read of the opportunity.

Ticket size
₹25 lakh to ₹5 crore
Per investment
Stage
Pre-seed to Series A+
Larger rounds through co-investment
Sectors
Healthcare, medtech, IVD, SaMD
FDA-regulated products
Capital
Our own family office
No fixed fund life
Why Tacticity Capital
The same judgment behind the consulting practice, now behind the capital.
Reviewer-side, not advisory-side
Tacticity Advisors was founded by a former U.S. FDA CDRH scientist and lead reviewer with 300+ device submissions reviewed. That same judgment underwrites every investment and diligence call Tacticity Capital makes.
Investment discipline, not just regulatory insight
Tacticity Capital's CFO founded Fintree and has spent close to two decades in Indian capital markets, including as portfolio advisor to family offices, UHNIs, and institutional investors. Regulatory judgment and investment discipline sit at the same table.
Patient capital, not a fixed clock
Backed by our own family office rather than a fund with a fixed fund life, Tacticity Capital can support portfolio companies through the actual timeline FDA review requires, not the timeline a typical fund structure allows.
How We Invest
A standard venture process, with diligence and scientific review at the center.
The steps will look familiar to any venture investor. What differs is where the weight sits: a reviewer-side read of the technology and its FDA pathway comes first, and scientific and regulatory diligence carry the most weight in the decision.
01
Sourcing and screening
Deals come from founders, angel groups, syndicates, and co-investors. A first screen checks stage, sector, ticket fit, and whether the product is a regulated healthcare technology.
Core of our process
02
Regulatory and scientific first read
A short reviewer-side read of the technology and its likely FDA pathway, before any deeper work. It decides whether a deal earns full diligence.
Core of our process
03
Full diligence
Scientific, regulatory, and commercial review run in parallel, with the most weight on the science and the pathway. The detail is set out below.
04
Decision and terms
Findings are written up plainly. Regulatory and scientific risk is priced into valuation and, where appropriate, tied to milestones in the terms.
05
Closing and onboarding
Documentation and closing, with a regulatory plan agreed with the founders from day one.
06
Support and follow-on
Regulatory support continues through each FDA milestone, and follow-on decisions are informed by real submission progress, not only a founder update.
Inside step 03
What full diligence covers.
Weighted most heavily
Scientific review
  • Whether the technology works as pitched: the mechanism, the performance claims, and the evidence behind them.
  • Data quality and integrity: how test data was generated, and whether the methods would stand up to FDA review.
  • Materials, biocompatibility, and chemistry for anything that contacts the body.
  • Whether the planned bench, analytical, and clinical evidence matches the claims being made.
  • Manufacturing and quality readiness: whether the product can be built consistently.
Regulatory review
  • FDA pathway and classification: 510(k), De Novo, PMA, or another route, and whether the claimed one is realistic.
  • Predicate strength and intended-use claims.
  • FDA interaction history: Form 483s, Warning Letters, deficiency responses, and pre-submission feedback.
  • Submission readiness, likely timeline, and the cost of reaching clearance or approval.
Commercial and financial review
  • Market, reimbursement, and adoption path.
  • Unit economics and use of proceeds, including the cost of regulatory and clinical work.
  • Team, cap table, intellectual property, and legal structure.
  • Run alongside co-investors where they are in the round, so the work is not duplicated.
The Team Behind the Capital
Reviewer-side judgment and investment discipline, in two people.
Tanmay Jain, PhD, Founder and Chief Scientist
Tanmay Jain, PhD
Founder & Chief Scientist

Former U.S. FDA CDRH scientist and lead reviewer with 300+ device submissions reviewed and co-author of ASTM F3718. His reviewer-side judgment informs every investment and diligence decision.

Utkarsh Jain, Chief Financial Officer
Utkarsh Jain
Chief Financial Officer

Founder and CEO of Fintree, with nearly two decades in Indian capital markets and a portfolio advisor to family offices and UHNIs. CA, CFA, FRM, CFP, LLB.

Meet the full team →

Raising capital, or evaluating a healthcare investment? Let's connect.

I Am a Founder Raising Capital I Am a Fund or Family Office